benzoate / caffeine Injection
- RxCUI
- 1729397
- RxNorm name
- benzoate / caffeine Injection
- Term type
- SCDF
- Status
- Active
- Updated
- 2026-10-29 07:11:36
RxNorm Status History#
- Status
- Active
- Source
- RXNORM
- Current
- YES
- Release start
- 022016
- Active start
- 022016
- Multiple ingredient
- YES
- Branded
- NO
Dose Form Concepts#
| Dose form | RxCUI |
|---|---|
| Injection | 1649574 |
Derived Ingredient Concepts#
Source Vocabulary Codes#
| Code type | Values | Count | Category |
|---|---|---|---|
| PRESCRIBABLE | Y | 1 | ATTRIBUTES |
| RXNAV_STR | benzoate / caffeine Injection | 1 | NAMES |
| RxNorm Name | benzoate / caffeine Injection | 1 | NAMES |
| TTY | SCDF | 1 | ATTRIBUTES |
| RxCUI | 1729397 | 1 | CODES |
UNII Substances#
No records found.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
No records found.
Drug Classes#
| Source | Class ID | Class | Type | Relationship | Drug concept |
|---|---|---|---|---|---|
| ATC | D11AX | Other dermatologicals | ATC1-4 | caffeine | |
| ATC | V04CG | Tests for gastric secretion | ATC1-4 | benzoate / caffeine | |
| ATC | A16AX | Various alimentary tract and metabolism products | ATC1-4 | sodium benzoate | |
| ATC | N06BC | Xanthine derivatives | ATC1-4 | caffeine | |
| FDASPL | D014970 | Xanthines | CHEM | has_chemical_structure | caffeine |
| FDASPL | N0000175739 | Central Nervous System Stimulant | EPC | has_epc | caffeine |
| FDASPL | N0000175790 | Methylxanthine | EPC | has_epc | caffeine |
| FDASPL | N0000175729 | Central Nervous System Stimulation | PE | has_pe | caffeine |
| MEDRT | D001565 | Benzoates | CHEM | has_ingredient | benzoate |
| MEDRT | D002110 | Caffeine | CHEM | has_ingredient | caffeine |
| MEDRT | D020160 | Sodium Benzoate | CHEM | has_ingredient | sodium benzoate |
| MEDRT | D001049 | Apnea | DISEASE | may_treat | caffeine |
| MEDRT | D004342 | Drug Hypersensitivity | DISEASE | ci_with | sodium benzoate |
| MEDRT | D004342 | Drug Hypersensitivity | DISEASE | ci_with | caffeine |
| MEDRT | D005221 | Fatigue | DISEASE | may_treat | caffeine |
| MEDRT | D006261 | Headache | DISEASE | may_treat | sodium benzoate |
| MEDRT | D022124 | Hyperammonemia | DISEASE | may_treat | sodium benzoate |
| MEDRT | N0000175806 | Ammonium Ion Binding Activity | MOA | has_moa | sodium benzoate |
| MEDRT | N0000000133 | Enzyme Inhibitors | MOA | has_moa | caffeine |
| MEDRT | N0000009915 | Unknown Cellular or Molecular Interaction | MOA | has_moa | sodium benzoate |
| MEDRT | N0000008322 | Bronchodilation | PE | has_pe | caffeine |
| MEDRT | N0000008331 | Cardiovascular Activity Alteration | PE | has_pe | caffeine |
| MEDRT | N0000008567 | Decreased Collecting Duct Water Permeability | PE | has_pe | caffeine |
| MEDRT | N0000009197 | Increased Central Nervous System Organized Electrical Activity | PE | has_pe | caffeine |
| MEDRT | N0000009458 | Increased Organic Ion Degradation | PE | has_pe | sodium benzoate |
| MEDRT | N0000009925 | Unknown Physiological Effect | PE | has_pe | sodium benzoate |
Properties#
| Category | Property | Value |
|---|---|---|
| ATTRIBUTES | GENERAL_CARDINALITY | MULTI |
| ATTRIBUTES | RXNAV_HUMAN_DRUG | US |